MG
EIDX

Michael Gelband’s Eidos Therapeutics, Inc. Common Stock EIDX Stock Holding History

Michael Gelband’s Portfolio EIDX Stock Details EIDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-8,851
Closed -$422K – 2425
2020
Q2 		$422K Buy
8,851
+4,472
+102% +$208K 0.01% 1161
2020
Q1 		$215K Buy
+4,379
New +$223K 0.01% 764
2019
Q4 		– Sell
-9,989
Closed -$359K – 2033
2019
Q3 		$359K Sell
9,989
-18,003
-64% -$703K 0.01% 802
2019
Q2 		$870K Buy
+27,992
New +$759K 0.03% 298

Other funds holding EIDX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

Michael Gelband's EIDX Position: Q3 2020 in Review

Michael Gelband sold out of Eidos Therapeutics, Inc. Common Stock (EIDX) in Q3 2020, closing a stake of 8,851 shares — an estimated $422K sold.

Michael Gelband first reported a position in EIDX in Q2 2019 and held it in 4 quarters. The position peaked at $870K in Q2 2019. 91 funds tracked by Wall St. Rank hold EIDX as of Q3 2020.

  • Michael Gelband reported no remaining Eidos Therapeutics, Inc. Common Stock position as of Q3 2020 after selling out during the quarter.
  • Michael Gelband sold 8,851 Eidos Therapeutics, Inc. Common Stock shares in Q3 2020, an estimated $422K.
  • Michael Gelband first reported a position in Eidos Therapeutics, Inc. Common Stock in Q2 2019 and held it in 4 quarters.
  • Michael Gelband's Eidos Therapeutics, Inc. Common Stock position peaked at $870K in Q2 2019.
  • 91 funds tracked by Wall St. Rank held Eidos Therapeutics, Inc. Common Stock as of Q3 2020.

Based on ExodusPoint Capital Management's 13F filing for Q3 2020, filed 16 Nov 2020.